Linezolid - A review of the first oxazolidinone

Expert Opinion on Pharmacotherapy

Volumn 2, Issue 2, 2001, Pages 293-302

  Norrby, R ^a  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

Author keywords

Enterococci; Gram positive bacteria; Linezolid; Methicillin resistant; Penicillin resistant; Pneumococci; Staphylococci; Vancomycin resistant

Indexed keywords

AMOXICILLIN; CEFPODOXIME; CEFTRIAXONE; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERYTHROMYCIN; GATIFLOXACIN; LEVOFLOXACIN; LINEZOLID; MACROLIDE; MONOAMINE OXIDASE INHIBITOR; MOXIFLOXACIN; OXACILLIN; OXAZOLIDINONE DERIVATIVE; PENICILLIN G; PROTEIN SYNTHESIS INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIBOSOME RNA; RNA 70S; TELITHROMYCIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ADRENERGIC SYSTEM; AEROBIC BACTERIUM; ANAEROBIC BACTERIUM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; CLINICAL TRIAL; COLITIS; COMMUNICABLE DISEASE; COMPLEX FORMATION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ENTEROCOCCUS; FEVER; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEADACHE; HUMAN; INSOMNIA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; NAUSEA; NONHUMAN; PATHOGENICITY; PENICILLIN RESISTANCE; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PSEUDOMEMBRANOUS COLITIS; RABBIT; RANDOMIZED CONTROLLED TRIAL; RASH; RAT; SEROTONINERGIC SYSTEM; SKIN INFECTION; SOFT TISSUE INFECTION; STREPTOCOCCUS PNEUMONIAE; SUSPENSION; TABLET FORMULATION; THROMBOCYTOPENIA; THROMBOPHLEBITIS; VERTIGO; VOMITING;

ACETAMIDES; ANIMALS; ANTI-BACTERIAL AGENTS; BIOLOGICAL AVAILABILITY; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; GRAM-NEGATIVE ANAEROBIC BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; OXAZOLIDINONES; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 0035001923     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2.2.293     Document Type: Article

References (48)

1. Prevalence of methicillin-resistant and methicillin-susceptible Staphyloccocus aureus in the community
2. The threat of vancomycin resistance
3. High prevalence of antibiotic resistance of common pathogenic bacteria in Taiwan
4. The association between antecedent vancomycin treatment and hospital-acquired vancomycin-resistant enterococci: A meta-analysis
5. Oxazolidinones, a new class synthetic antibacterial agents: In vitro and in vivo activities of DuP 105 and DuP 721
6. Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multi-drug resistant Gram-positive bacterial infections
7. Design, synthesis and evaluation of novel oxazolidinone antibacterial agents active against multidrug-resistant bacteria
8. Mechanisms of action of the oxazolidinones: Effects of linezolid and eperezolid on translation reactions
9. On the target of a novel class of antibiotics, oxazolidinones, active against multidrug-resistant Gram-positive
10. Ribosomal RNA is the target for exazolidinones, a novel class of translational inhibitors
11. Resistance mutations in the 23 S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyl transferase center
12. In vitro antimicrobial activities and spectra of U-100592 and U-100766m two novel fluorinated oxazolidinones
13. In vitro activities of the oxazolidinones U-100592 and U-100766 against Staphylococcus aureus and coagulase-negative Staphylococcus species
14. Comparative in vitro and bactericial activity of oxazolidinone antibiotics against multidrug-resistant enterococci
15. In vitro activities of new oxazolidinones antimicrobial agents against enterococci
16. Linezolid activity compared to those of selected macrolides and other agents against aerobic and anaerobic pathogens isolated from soft tissue bite infections in humans
17. The in-vitro activity of linezolid and tentative breakpoints
18. Susceptibilities of Legionella spp. to newer antimicrobial in vitro
19. In vitro activities of oxazolidinones U-100592 and U-100766 against penicillin-resistant and cephalosporin-resistant strains of Streptococcus pneumoniae
20. MICs of oxazolidinones for Rhodococcus equi strains isolated from human and animals
21. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents
22. Activity of linezolid against and multi-resistant Gram-positive bacteria from diverse hospitals in the United Kingdom
23. Oxazolidinones. A review
24. In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Stapbylococcus epidermidis
25. Linezolid
26. Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model
27. Determination of linezolid in plasma by reverse-phase high- performance liquid chromatography
28. Linezolid safety, tolerance and pharmacokinetics following oral dosing twice daily for 14.5 days
29. Linezolid safety, tolerance and pharmacokinetics following intravenous dosing twice daily for 7.5 days
30. Effects of age and gender on the single-dose pharmacokinetics of linezolid
31. Pharmacokinetics of linezolid in subjects with various degrees of renal failure
32. Pharmacokinetics of linezolid in patients with liver disease
33. In vitro metabolism of linezolid (PNU-100766): Lack of induction or inhibition of cytochrome P450 enzymes and studies on mechanism of formation of the major human metabolite, PNU-142586
34. 14C]PNU 100766 to healthy human volunteers
35. The pharmacodynamic activity and efficacy of linezolid in a rat model of pneumococcal pneumonia
36. Linezolid in the treatment of streptococcal skin and soft tissue infections: Combined results from three Phase III trials
37. Linezolid in the treatment of staphylococcal skin and soft tissue infections: Combined results from three Phase III trials
38. Clinical efficacy of linezolid (LZD) for complicated skin and soft tissue infections caused by MRSA
39. Comparison of linezolid versus ceftriaxone/cefpodoxime in the treatment of hospitalized patients with community acquired pneumonia: European results
40. Linezolid eradicates common pathogens in community-acquired pneumonia
41. Linezolid's effects on early hospital discharge in hospitalized patients with complicated skin and soft tissue infections (cSSTI) under varying rates of methicillin-resistant staphylococcus (MRS) infection: Analysis two randomized clinical trials (RCTs)
42. Re-examining hospital length of stay (LOS) reduction potential in a randomized, multi-center clinical trials of methicillin-resistant staphylococci species: Linezolid vs. vancomycin
43. Safety and tolerance of linezolid: Adverse events reported in Phase III trials
44. Incidence of Clostridium difficile related complications during clinical trials of linezolid, an oxazolidinone
45. Incidence of intravenous catheter-related complications during clinical trials of linezolid, an oxazolidione
46. Pharmacostatistical modelling of hematological effects of linezolid in seriously ill patients
47. Lack of serotonin syndrome in Phase III patients receiving linezolid and a selective serotonin reuptake inhibitor (SSRI)